15038 studies
BACKGROUND Cutaneous allodynia is reported as a pain resulting from a stimulus that does not normally provoke or elicit pain and an altered quality of sensation characterized by extreme sensitivity to touch or mild temperature change. Glucagon-like p…
AIMS: We evaluated the impact of tirzepatide on health-related quality of life (HR-QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT-J trial. MATERIALS AND METHODS: Japanese adults with obesity disease without diabetes were…
Tirzepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, is increasingly prescribed for obesity and glycemic control. Its effects on gastric emptying, appetite regulation, and rapid weig…
BACKGROUND: In the SURPASS-CVOT trial, tirzepatide, a dual incretin agonist that targets the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, was shown to be non-inferior to dulaglutide for the primary composite car…
Mitochondrial dysfunction and insufficient mitophagy are central to cisplatin-induced acute kidney injury (AKI). Tirzepatide, a dual GLP‑1/GIP receptor agonist, exhibits reno-protective effects, but its mechanism related to mitochondrial homeostasis…
BACKGROUND: Sepsis-associated acute lung injury (ALI) is characterized by unregulated systemic inflammation, disruption of the redox balance, and impaired pulmonary function. Tirzepatide, a synthetic dual GLP-1 and GIP receptor agonist possessing ant…
BACKGROUND: Obesity treatment improves long-term health and quality of life outcomes. Weight reduction and its maintenance play an important role in achieving these goals. We evaluated the efficacy and safety of continuing tirzepatide at the maximum…
Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated protective effects against chronic kidney disease, their impact on acute kidney injury (AKI) remains unclear. AKI…
Carrying a germline mutation inis associated with an increased risk of several cancers, including breast and ovarian. Our recent work has demonstrated that obesity is associated with elevated levels of DNA damage in breast glands in this high-risk po…
BACKGROUND: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its e…
(), a novel highly potent GLP-1/GIP dual agonist, was engineered via computational alanine scanning and rational acylation design. Nonacylated() showed stable receptor binding and higher affinity than nonacylatedin molecular dynamics simulations and…
OBJECTIVES: Depression, diabetes, and obesity often coexist, forming a complex "metabolic-mood syndrome" characterized by inflammation, impaired neuroplasticity, and neuroendocrine dysregulation. Conventional antidepressants show limited efficacy in…
BACKGROUND: Obesity is characterized by chronic inflammation and fibrosis of adipose tissue; however, the extent to which these pathological features persist during pharmacologically induced weight loss remains poorly understood. This study investiga…
Obstructive sleep apnea syndrome (OSAS) is closely associated with obesity and metabolic dysfunction. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated superior efficacy for weight reduction and improved metabolic health compared w…
[This corrects the article DOI: 10.3389/fphar.2026.1735987.].
IMPORTANCE: Overweight and obesity affect 60% to 78% of patients with psoriasis, affecting disease severity, treatment response, and clinical outcomes. However, no large, randomized, active-controlled clinical trial has evaluated a treatment strategy…
PURPOSE OF REVIEW: To summarize key findings from cardiovascular disease prevention trials at the 2026 American College of Cardiology (ACC) Conference. RECENT FINDINGS: The Ez-PAVE trial demonstrated that targeting low-density lipoprotein cholesterol…
We report the case of a 53-year-old woman with type 2 diabetes and bulimia nervosa who developed prolonged paralytic ileus after self-injecting tirzepatide 7.5 mg, 10 mg, and 15 mg on three consecutive days. Tirzepatide had been prescribed for diabet…
The dual GLP-1/GIP agonist tirzepatide is a highly effective anti-obesity therapy. While promising, it is associated with potential adverse effects, including thyroid disease reported in animal models. Due to limited human data, this study seeks to i…